Real-world utilization of andexanet alfa

We read with interest the online article by Brown et al. [1], describing their use of andexanet alfa in reversing factor Xa inhibitors, specifically apixaban and rivaroxaban. The authors were mostly consistent with the trial [2], although they interestingly included patients that would have been excluded in ANNEXA-4 (e.g. patients with a Glasgow Coma Scale (GCS) of less than 7, initial hematoma volume of more than 60  mL and patients undergoing a procedure in the next 12 h). We appreciate the authors efforts to increase the reporting of clinical data with use of andexanet alfa, however, some concerns still remain.

Source: The American Journal of Emergency Medicine - January 22, 2020 Category: Emergency Medicine Authors: Caroline Bernard, Eric Villeneuve, Madeleine Genest, Sophie Gosselin Tags: Correspondence Source Type: research